



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Aniracetam (Standard)

Cat. No.:	HY-10932R
CAS No.:	72432-10-1
Molecular Formula:	C ₁₂ H ₁₃ NO ₃
Molecular Weight:	219.24
Target:	nAChR; iGluR
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Aniracetam (Standard) is the analytical standard of Aniracetam. This product is intended for research and analytical applications. Aniracetam (Ro 13-5057) is an orally active neuroprotective agent, possessing nootropic effects. Aniracetam potentiates the ionotropic quisqualate (iQA) responses in the CA1 region of rat hippocampal slices. Aniracetam also potentiates the excitatory post synaptic potentials (EPSPs) in Schaffer collateral-commissural synapses. Aniracetam can prevent the CO₂-induced impairment of acquisition in hypercapnia model rats. Aniracetam can be used to research cerebral dysfunctional disorders^{[1][2][3][4]}.

REFERENCES

- [1]. Nakamura K, et al. Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. *Eur J Pharmacol.* 2001 May 18;420(1):33-43.
- [2]. Vaglenova J, et al. Aniracetam reversed learning and memory deficits following prenatal ethanol exposure by modulating functions of synaptic AMPA receptors. *Neuropsychopharmacology.* 2008 Apr;33(5):1071-83. Epub 2007 Jul 4.
- [3]. Ito I, et al. Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. *J Physiol.* 1990 May;424:533-43.
- [4]. Cumin R, et al. Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. *Psychopharmacology (Berl).* 1982;78(2):104-11.
- [5]. Nakamura K. Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries. *CNS Drug Rev.* 2002 Spring;8(1):70-89.
- [6]. Pizzi M, et al. Attenuation of excitatory amino acid toxicity by metabotropic glutamate receptor agonists and aniracetam in primary cultures of cerebellar granule cells. *J Neurochem.* 1993 Aug;61(2):683-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA